Report Library
All ReportsDatamonitor Healthcare Oncology: Bladder Cancer Disease Coverage
September 27, 2018
Bladder cancer is the fifth most common cancer in Europe and the ninth most common cancer globally. Symptoms include hematuria,
dysuria,
increased urinary frequency, and frequent urinary tract infections. Urothelial carcinoma, also known as transitional cell carcinoma,
accounts
for
over 90% of bladder cancers. Approximately three-quarters of urothelial carcinoma patients initially present with non-muscle invasive
bladder
cancer (NMIBC), which is associated with a relatively good prognosis. However, NMIBCs are characterized by a high risk of recurrence,
leading to a high disease burden and making bladder cancer one of the costliest malignancies to treat.
This Datamonitor Healthcare Disease Coverage report contains Forecast, Treatment, Epidemiology, Marketed Drugs, Pricing & Reimbursement, and Pipeline modules.
This Datamonitor Healthcare Disease Coverage report contains Forecast, Treatment, Epidemiology, Marketed Drugs, Pricing & Reimbursement, and Pipeline modules.
Indications Covered: | Bladder Cancer |